Academic Unit of Surgery, School of Medicine, University of Glasgow, Royal Infirmary, Glasgow G31 2ER, UK.
Unit of Experimental Therapeutics, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.
Br J Cancer. 2018 Mar 6;118(5):705-712. doi: 10.1038/bjc.2017.441. Epub 2018 Jan 16.
There has been an increasing interest in the role of tumour location in the treatment and prognosis of patients with colorectal cancer (CRC), specifically in the adjuvant setting. Together with genomic data, this has led to the proposal that right-sided and left-sided tumours should be considered as distinct biological and clinical entities. The aim of the present study was to examine the relationship between tumour location, tumour microenvironment, systemic inflammatory response (SIR), adjuvant chemotherapy and survival in patients undergoing potentially curative surgery for stage I-III colon and rectal cancer.
Clinicopathological characteristics were extracted from a prospective database. MMR and BRAF status was determined using immunohistochemistry. The tumour microenvironment was assessed using routine H&E pathological sections. SIR was assessed using modified Glasgow Prognostic Score (mGPS), neutrophil:lymphocyte ratio (NLR), neutrophil:platelet score (NPS) and lymphocyte:monocyte ratio (LMR).
Overall, 972 patients were included. The majority were over 65 years (68%), male (55%), TNM stage II/III (82%). In all, 40% of patients had right-sided tumours and 31% had rectal cancers. Right-sided tumour location was associated with older age (P=0.001), deficient MMR (P=0.005), higher T stage (P<0.001), poor tumour differentiation (P<0.001), venous invasion (P=0.021), and high CD3 within cancer cell nests (P=0.048). Right-sided location was consistently associated with a high SIR, mGPS (P<0.001) and NPS (P<0.001). There was no relationship between tumour location, adjuvant chemotherapy (P=0.632) or cancer-specific survival (CSS; P=0.377). In those 275 patients who received adjuvant chemotherapy, right-sided location was not associated with the MMR status (P=0.509) but was associated with higher T stage (P=0.001), venous invasion (P=0.036), CD3 at the invasive margin (P=0.033) and CD3 within cancer nests (P=0.012). There was no relationship between tumour location, SIR or CSS in the adjuvant group.
Right-sided tumour location was associated with an elevated tumour lymphocytic infiltrate and an elevated SIR. There was no association between tumour location and survival in the non-adjuvant or adjuvant setting in patients undergoing potentially curative surgery for stage I-III colon and rectal cancer.
人们对肿瘤位置在结直肠癌(CRC)患者治疗和预后中的作用越来越感兴趣,尤其是在辅助治疗方面。结合基因组数据,这导致人们提出右侧和左侧肿瘤应被视为不同的生物学和临床实体。本研究旨在检查肿瘤位置、肿瘤微环境、全身炎症反应(SIR)、辅助化疗与接受 I-III 期结肠癌和直肠癌潜在根治性手术患者的生存之间的关系。
从一个前瞻性数据库中提取临床病理特征。使用免疫组织化学法确定错配修复(MMR)和 BRAF 状态。使用常规 H&E 病理切片评估肿瘤微环境。使用改良格拉斯哥预后评分(mGPS)、中性粒细胞/淋巴细胞比值(NLR)、中性粒细胞/血小板比值(NPS)和淋巴细胞/单核细胞比值(LMR)评估 SIR。
总共纳入 972 例患者。大多数患者年龄超过 65 岁(68%),男性(55%),TNM 分期 II/III 期(82%)。总的来说,40%的患者为右侧肿瘤,31%为直肠肿瘤。右侧肿瘤位置与年龄较大(P=0.001)、MMR 缺陷(P=0.005)、较高 T 分期(P<0.001)、肿瘤分化差(P<0.001)、静脉侵犯(P=0.021)和癌巢内 CD3 较高(P=0.048)相关。右侧位置与高 SIR、mGPS(P<0.001)和 NPS(P<0.001)一致相关。肿瘤位置与辅助化疗(P=0.632)或癌症特异性生存(CSS;P=0.377)之间没有关系。在接受辅助化疗的 275 例患者中,右侧位置与 MMR 状态无关(P=0.509),但与较高 T 分期(P=0.001)、静脉侵犯(P=0.036)、浸润边缘的 CD3(P=0.033)和癌巢内的 CD3(P=0.012)相关。辅助组中肿瘤位置、SIR 或 CSS 之间没有关系。
右侧肿瘤位置与肿瘤淋巴细胞浸润增加和 SIR 升高有关。在接受潜在根治性手术的 I-III 期结肠癌和直肠癌患者中,肿瘤位置与非辅助或辅助治疗的生存之间没有关联。